A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
New Product Review (September 2003) Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra®)
2004
Journal of family planning and reproductive health care
Inevitably there are limited long-term safety data for any new contraceptive method, in particular regarding venous thromboembolism and breast or cervical cancer risk. Detailed scientific studies, performed in a small number of women, provide evidence on mode of action. Larger clinical trials examine efficacy, side effects and acceptability. The number of woman-years of exposure is less than for established methods and all available evidence should be considered before prescribing new products.
doi:10.1783/147118904322701974
pmid:15006313
fatcat:aurdukmn4rd53dbqkbsm4iiizq